Nuvalent Inc.
Nuvalent Reports Q4 and Full Year 2024 Financial Results and Business Updates
Summary
Nuvalent, Inc. reported its financial results for the quarter and year ended December 31, 2024, revealing a cash position of $1.1 billion as of December 31, 2024, with R&D expenses of $69.4 million for Q4 2024 and $217.8 million for the full year. The company also outlined significant progress in its pipeline, including expected pivotal data in 2025 for its TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC programs, and initiation of the ALKAZAR Phase 3 trial for neladalkib in the first half of 2025. Nuvalent also announced the launch of global Expanded Access Programs for zidesamtinib and neladalkib, and the appointment of Grant Bogle to its Board of Directors in December 2024.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement